|Bid||40.00 x 1200|
|Ask||42.32 x 1200|
|Day's Range||39.54 - 42.70|
|52 Week Range||16.50 - 42.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.60|
NEW HAVEN, Conn. and NEW YORK, June 18, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") and Royalty Pharma announced today that Biohaven has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000) or BHV-3500 and certain derivative compounds thereof to Royalty Pharma for $100 million. Royalty Pharma has also agreed to purchase $50.0 million in common shares of Biohaven, at a price of $45.00 per share, representing an approximately 19% premium over the 15-day volume-weighted average price through June 15, 2018.
NEW HAVEN, Conn., June 13, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, today announced that Ernst & Young (EY) named Biohaven CEO Vlad Coric as the Entrepreneur Of The Year® 2018 Award winner in the Health Care category in the New York region. The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities.
Presentations include clinically meaningful, comprehensive and durable benefits observed in two pivotal Phase 3 clinical trials of rimegepant for the acute treatment of migraine NEW HAVEN, Conn. , June ...
In December 2017, Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) released its latest earnings announcement, which signalled that losses became smaller relative to the prrior year’s level as a result ofRead More...
-- Successful Achievement of Registrational Co-Primary Endpoints and Key Secondary Endpoints in Two Pivotal Phase 3 Trials with Rimegepant (Oral CGRP Receptor Antagonist) for the Acute Treatment of Migraine, ...
This Wednesday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: AveXis Inc. (NASDAQ: AVXS), Biogen Inc. (NASDAQ: BIIB), Biohaven Pharmaceutical Holding Co. Ltd, (NYSE: BHVN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN): All you have to do is sign up today for this free limited time offer by clicking the link below. On Tuesday, shares in Bannockburn, Illinois headquartered AveXis Inc. recorded a trading volume of 941,320 shares, which was above their three months average volume of 884.73 thousand shares. The Company's shares have gained 88.91% over the previous three months and 181.89% in the past twelve months.
NEW HAVEN, Conn., May 9, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) today announced that it has established an expanded access program (EAP) with sublingual BHV-0223, an investigational drug candidate, for patients with amyotrophic lateral sclerosis (ALS). Through this program, physicians may be able to obtain BHV-0223 for their eligible patients with ALS at no cost. BHV-0223 is a sublingual and lower dose formulation of riluzole which employs the Zydis® orally dissolving tablet technology and does not require swallowing tablets or additional fluids.
- Durability of clinical effect was seen across multiple outcome measures and findings were consistent across both pivotal Phase 3 trials. - A single dose of rimegepant, without any rescue medications, was superior to placebo for pain freedom and pain relief at 2 hours post-dosing, and showed a profile of increasing improvement throughout the first eight hours that was sustained compared to placebo out to 24 and 48 hours. - The vast majority of rimegepant treated patients did not take rescue medications during the 24 hour period after dosing.
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Data detailing single-dose durable headache relief and recovery of function endpoints from the two pivotal Phase 3 studies of rimegepant, Biohaven's oral CGRP receptor antagonist. - Leading migraine ...
NEW HAVEN, Conn. , April 5, 2018 /PRNewswire/ -- Kleo Pharmaceuticals, a biopharmaceutical company developing innovative small molecule immunotherapies, announced today that CEO Doug Manion , M.D. FRCP ...
NEW HAVEN, Conn., April 3, 2018 /PRNewswire/ -- Kleo Pharmaceuticals Inc., a biotechnology company pioneering a new class of immunotherapies utilizing small molecules to activate an individual's own immune system to fight against cancers and other diseases, announced today the appointment of Luca Rastelli PhD, as Chief Scientific Officer, effective immediately and reporting to Doug Manion, CEO. Dr. Rastelli will lead all aspects of R&D for the company and serve as the scientific external face of Kleo Pharmaceuticals to the investor, scientific, medical and patient communities. "We welcome Luca to the Kleo Pharmaceuticals executive team," said Kleo's Chief Executive Officer, Doug Manion, M.D., FRCP(C).
Stock Monitor: Cytori Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Biohaven Pharma Holding Co. Ltd. (NYSE: ...
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) investors took their profits Monday after the firm reported positive Phase 3 data for rimegepant. One analyst considers the related sell-off an entry ...
The week is now well underway and there are a couple of major developments in the biotechnology space, both of which are related to the release of clinical trial data and both of which have translated to some real volatility in the market capitalization of the companies to which they relate. The two companies in […] The post Here’s What’s Moving AnaptysBio and Biohaven Pharmaceutical appeared first on Market Exclusive.
Biohaven fell more than 30% early Monday after it unveiled the results of two late-stage trials for its migraine drug.
Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment. In February, Allergan reported strong efficacy data for its migraine treatment, ubrogepant. A late entrant to the competitive arena of migraine treatments, Connecticut-based Biohaven's rimegepant is part of a new class of medicines called CGRP receptor antagonists.
Biohaven Pharmaceutical Holding Co. Ltd. shares dropped nearly 23% in premarket trade Monday after the company released data from two phase 3 clinical trials for its migraine drug rimegepant. The company ...
- Rimegepant met both registrational co-primary endpoints (pain freedom and freedom from most bothersome symptom at 2 hours) in two pivotal Phase 3 trials - Results are statistically significant and clinically ...
Biohaven Pharmaceutical Holding Company Ltd’s (NYSE:BHVN): Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The US$1.07B market-cap company announcedRead More...
Investors in Biohaven Pharmaceutical (BHVN) need to pay close attention to the stock based on moves in the options market lately.
NEW HAVEN, Conn., March 12, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company") announced today a restructuring of its global license agreement with Bristol-Myers Squibb Company (BMY) ("BMS") for Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist platform, which includes its product candidates rimegepant, a potentially best-in-class CGRP receptor antagonist for the acute treatment of migraine, and BHV-3500, a third-generation antagonist for the acute treatment and prevention of migraine. As part of the restructuring, Biohaven will pay BMS an upfront payment of $50 million in return for a low single digit reduction in the royalties payable on net sales of rimegepant and a mid-single digit reduction in the royalties payable on net sales of BHV-3500.
NEW HAVEN, Conn., March 6, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and year ended December 31, 2017 and provided a review of recent accomplishments and anticipated upcoming milestones.